Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNU6-522P** (U6 small nuclear RNA 522 pseudogene) is classified as a non-coding RNA pseudogene derived from the U6 small nuclear RNA (snRNA) gene family. U6 snRNA is an essential component of the spliceosome, which mediates the splicing of pre-mRNA in the nucleus of eukaryotic cells[3][1]. Pseudogenes like RNU6-522P represent non-functional, typically non-expressed genomic sequences that arose by duplication or retrotransposition of the functional U6 snRNA gene[2][4]. These pseudogenes are evolutionarily common and thought to play no major direct biological role, though they can provide insight into genome evolution and gene family history[3][2]. There is no evidence that RNU6-522P encodes a functional RNA or protein, interacts with drugs, serves as a disease biomarker, or constitutes a therapeutic target. It is not considered a receptor, enzyme, transporter, or any other classical drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U6 small nuclear RNA 522 pseudogene (RNU6-522P).